Fig. 1

Effect of inhibiting platelet activation on intestinal barrier function in septic mice. Cilostazol (10 mg/kg) was administrated orally 2 h prior to and at 12 h after CLP to inhibit platelet activation. 24 h after CLP, mice were sacrificed, and tissue samples were collected. a The survival rate of the mice within 7 days after CLP was observed by survival curves (n = 10). b–f Intestinal barrier permeability was indicated by serum FITC-Dextran levels (b) (n = 6), water content (c) of gut (n = 6), and colony-forming units (CFUs) (d–f) from mesenteric lymph node (MLN), liver and lung (n = 6). g, h Haematoxylin and eosin (H&E) staining and pathological score, Scale bar = 100 μm (n = 6). i, j Western blot analysis of ZO-1 and occludin expression (n = 6). k, l TNF-α and IL-1β levels in intestinal tissues (n = 6). m, n Immunofluorescence staining analysis of ZO-1 (red), Scale bar = 50 μm (n = 6). The data are presented as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001